Bio News
UK-based Compass Pathways said it plans to use the interventional psychiatry clinic infrastructure established by Spravato to launch COMP360 if it receives approval from the US Food and Drug Administration (FDA).
There are currently approximately 8,500 interventional psychiatry clinics across the United States, and Compass has expanded its commercial organization from 20 employees at the beginning of the year to approximately 100.
Compass designed COMP360 to be administered one to four times annually to improve treatment adherence. The company plans to carefully manage its initial patients before rapidly expanding.
Biobook Team
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
